Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental administration history that dates back to the 1950s.

"Having invested considerable time and resources in producing our own cGMP 2-bromo-d-LSD and in completing our IND-enabling preclinical toxicology work, we are excited to have commenced this clinical trial with the dosing of the first participant," said the company’s founder and CEO, Carey Turnbull. 

The company is aiming to …

Full story available on Benzinga.com